Preventing Cardiomyopathy in DMD: A Randomized Placebo-Controlled Drug Trial

Area of Science:

• Cardiology
• Neurology
• Genetics

Background:

• Duchenne muscular dystrophy (DMD) is a progressive genetic disorder affecting muscle tissue, leading to significant cardiac complications, including cardiomyopathy.
• Early intervention strategies are crucial to mitigate the progression of cardiac dysfunction in DMD patients.
• Previous studies suggested potential benefits of prophylactic heart medications, necessitating further investigation.

Purpose of the Study:

• To evaluate the safety and efficacy of a combination therapy (perindopril and bisoprolol) in preventing or delaying cardiomyopathy in boys with DMD.
• To compare the change in left ventricular ejection fraction (LVEF) between the combination therapy group and a placebo group over 36 months.

Main Methods:

• A multicenter, randomized, placebo-controlled trial involving boys with DMD aged 5-13 years and normal ventricular function.
• Participants received either prophylactic perindopril and bisoprolol or a placebo, with assessments of LVEF and adverse events conducted every six months.
• The primary outcome was the difference in LVEF change between the groups after 36 months.

Main Results:

• Combination therapy was well-tolerated, with no cardiac-related serious adverse events reported.
• No significant difference in the decline of LVEF was observed between the active treatment and placebo groups over 36 months.
• Four boys in the placebo group, but none in the active treatment group, were withdrawn due to worsening LV function.

Conclusions:

• Combination perindopril and bisoprolol therapy is safe and well-tolerated in boys with DMD.
• The study did not demonstrate a significant group benefit in preventing or delaying the decline of LVEF over 36 months.
• Further research may be needed to explore alternative or adjusted therapeutic strategies for cardiac protection in DMD.